
Colorado governor unveils plans for walkway in honor of the state's 150th birthday
Polis said the Colorado 150 Pedestrian Walkway will improve accessibility among downtown Denver's public spaces and help revitalize the Civic Center area.
Gov. Jared Polis
Gov. Jared Polis
The winding design will mimic the state's rivers and feature materials like sandstone, marble and granite, highlighting Colorado's geology. The governor's office said the walkway will include:
Viewing platforms
Sculptural monuments
Newly commissioned artwork from Colorado artists
Play elements
Learning and storytelling opportunities
"I'm thrilled that Coloradans can now visualize this walkway and its amazing positive impact on our community. Now, when Coloradans of all ages come to visit our State Capitol, they can more easily access and enjoy Lincoln Veterans Park while enjoying and learning from art from local artists. This interactive experience will showcase Colorado's history and look to our even stronger future. I want to thank Studio Gang for their work on this design, as well as all of the local artists who are going to make this walkway an important piece of public art for all to enjoy," said Polis.
Gov. Jared Polis
Gov. Jared Polis
The 11,000-foot walkway is part of a partnership between the governor's office, P3 Office at the Colorado Department of Personnel & Administration and History Colorado. It is expected to be completed in the Summer of 2026.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Exclusive-US pharma tariffs likely weeks away as Trump plans for Alaska, sources say
By Maggie Fick, Andrea Shalal and Dave Graham WASHINGTON (Reuters) -The announcement by President Donald Trump's administration of the results of a probe into pharmaceutical imports and new sector-specific U.S. tariffs likely remains weeks away, four official and industry sources said, later than initially promised as he focuses on other matters. Commerce Secretary Howard Lutnick had said in April when the review of whether reliance on foreign drug production threatens U.S. national security was launched that he anticipated that it would conclude between mid-May and mid-June. Global pharmaceutical companies are bracing for the outcome of the investigation, which will usher in sector-specific tariffs that Trump has said could start small and eventually rise to 250%. The Republican president said as recently as last week that his plan relies on phased-in tariffs, giving drugmakers time to increase manufacturing in the United States as he pushes to alter what he says are global trade distortions in many industries. One government official in Europe and a source with knowledge of the White House process, as well as two sources at European drug firms familiar with the process, told Reuters that the report and tariffs announcement was not imminent and likely weeks away. These sources spoke on condition of anonymity. A White House spokesperson, asked about media reporting indicating that the results of the probe could be several weeks away, cautioned that such reports were pure speculation unless confirmed by the White House. The spokesperson declined to give further details about the timing of the pharma probe or one involving semiconductors. The investigation is examining pharmaceutical imports ranging from finished prescription drugs to active pharmaceutical ingredients, called APIs, and other raw materials, with the results to be disclosed in a Commerce Department report. Lutnick said last month the tariff plan that will be based on the report would be completed by the end of July. Lutnick then said on July 29 it would be two more weeks. The investigation was launched under Section 232 of the Trade Expansion Act of 1962. While the investigation is ongoing, the pharmaceutical sector has been exempted from the sweeping tariffs imposed by the Trump administration. The United States has reached bilateral trade deals with the UK, Japan, South Korea and the European Union that promised more favorable terms for their pharma exports than those expected to be levied on the sector globally. A European government official said that an announcement before the end of August appears unlikely but cautioned that the timeline could shift depending on other developments. A source at a European drugmaker said the Trump administration is focused on the U.S.-Russia summit in Alaska on Friday and therefore no announcement is expected this week. The source familiar with the White House process said that announcement is unlikely to come this week given other priorities. That source and one other source said that they expect the Trump administration to announce the results of its national security investigation into semiconductors first, followed by the pharma announcement, putting it a few weeks away. The Section 232 provision authorizes the president to adjust imports - including imposing tariffs - if a category of goods is being imported into the United States in quantities that "threaten or impair the national security." Medical goods historically have been spared from trade wars due to the potential harm to patient access, and drugmakers have said tariffs could undercut other health policy goals outlined by the Trump administration, including lowering drug prices. U.S. tariffs on imported pharmaceutical products would mark the latest in a series of sectoral tariffs announced by the administration, following metals and cars, that some economists have predicted will drive up costs for American consumers.


Axios
4 minutes ago
- Axios
Polis dangles $280M to force housing policy changes
Colorado Gov. Jared Polis is flexing his muscle by making $280 million in grants to local authorities contingent on whether they adopt his housing policies. Why it matters: It's a high-stakes showdown between a steadfast governor who is hanging his legacy on creating more affordable housing and municipalities that consider the move bullying and a violation of the law. State of play: Polis put his plan into motion back in May, but in a new executive order issued Wednesday, he tightened his grip. Beginning Oct. 6, local governments will get scored on whether they are adopting recent policies to encourage affordable housing with $280 million across 34 grants, CPR first reported. The ones "working to ensure that every Coloradan has an affordable place to call home" will get priority, the order states. Between the lines: Among the housing policies Polis wants local governments to adopt: higher occupancy limits, permitting accessory dwelling units, eliminating parking restrictions on developments and building near transit hubs. What he's saying: "This is Colorado taxpayer money. We want to make sure that it's going to areas that are fundamentally pro-housing and are not kind of just rowing upstream and getting less housing," Polis told CPR.


CBS News
5 minutes ago
- CBS News
Appeals court allows Trump administration to cut billions in foreign aid
Washington — A divided panel of appeals court judges ruled Wednesday that the Trump administration can suspend or terminate billions of dollars of congressionally appropriated funding for foreign aid. Two of three judges from the U.S. Court of Appeals for the District of Columbia Circuit concluded that grant recipients challenging the freeze did not meet the requirements for a preliminary injunction that restored the flow of money. In January, on the first day of his second term in the White House, President Trump issued an executive order directing the State Department and the U.S. Agency for International Development to freeze spending on foreign aid. After groups of grant recipients sued to challenge that order, U.S. District Judge Amir Ali ordered the administration to release the full amount of foreign assistance that Congress had appropriated for the 2024 budget year. The appeal court's majority partially vacated Ali's order. Judges Karen LeCraft Henderson and Gregory Katsas concluded that the plaintiffs did not have a valid legal basis for the court to hear their claims. The ruling was not on the merits of whether the government unconstitutionally infringed on Congress' spending powers. "The parties also dispute the scope of the district court's remedy but we need not resolve it ... because the grantees have failed to satisfy the requirements for a preliminary injunction in any event," Henderson wrote. Judge Florence Pan, who dissented, said the Supreme Court has held "in no uncertain terms" that the president does not have the authority to disobey laws for policy reasons. "Yet that is what the majority enables today," Pan wrote. "The majority opinion thus misconstrues the separation-of-powers claim brought by the grantees, misapplies precedent, and allows Executive Branch officials to evade judicial review of constitutionally impermissible actions." The money at issue includes nearly $4 billion for USAID to spend on global health programs and more than $6 billion for HIV and AIDS programs. Mr. Trump has portrayed the foreign aid as wasteful spending that does not align with his foreign policy goals. Henderson was nominated to the court by Republican President George H.W. Bush. Katsas was nominated by Trump. Pan was nominated by Democratic President Joe Biden.